Active Protocols at the Clinic
Our team has rigorous guidelines in place to protect the well-being and safety of clinical trial participants, who are, of course, always fully aware of their participation. This research is carried out in collaboration with Greek and international academic and research institutions and usually results in publication of research papers in peer review journals.
3000-03-005/ENGOT-OV44 (FIRST): A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Non mucinous Epithelial Ovarian Cancer
RAD1901-308 (EMERALD): ELACESTRANT Monotherapy VS. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial
CA209-651: An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic cancer of the Head and Neck.
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access (EORTC)